The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer

Biomaterials

Volumn 35, Issue 15, 2014, Pages 4565-4572

  Zhang, Zhiwen ^a   Niu, Baohua ^b   Chen, Jian ^c   He, Xinyu ^b   Bao, Xiaoyue ^b   Zhu, Jianhua ^c   Yu, Haijun ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Cancer metastasis; Gastric cancer; Nanodiamond; Oral delivery; Sorafenib

Indexed keywords

BIOCHEMISTRY; DISEASES; DRUG DELIVERY; ENZYME INHIBITION; LOADING; PATHOLOGY; SUSPENSIONS (FLUIDS); TUMORS;

CANCER METASTASIS; GASTRIC CANCERS; GASTROINTESTINAL TRACT; HISTOLOGICAL EXAMINATION; ORAL BIOAVAILABILITIES; ORAL DELIVERY; SORAFENIB; TUMOR XENOGRAFT MODELS;

NANODIAMONDS;

LIPID COATED NANODIAMOND; NANODIAMOND; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY METASTASIS; LIVER METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR XENOGRAFT;

CANCER METASTASIS; GASTRIC CANCER; NANODIAMOND; ORAL DELIVERY; SORAFENIB;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; HUMANS; LIPIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANODIAMONDS; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; STOMACH; STOMACH NEOPLASMS;

EID: 84896051529     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.024     Document Type: Article

References (42)

1. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12:39-50.
2. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
3. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
4. Guggenheim D.E., Shah M.A. Gastric cancer epidemiology and risk factors. JSurg Oncol 2013, 107:230-236.
5. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
6. Peng C.W., Tian Q., Yang G.F., Fang M., Zhang Z.L., Peng J., et al. Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. Biomaterials 2012, 33:5742-5752.
7. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012, 4:156-169.
8. Wong H., Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?. Oncologist 2012, 17:346-358.
9. Che X., Hokita S., Natsugoe S., Tanabe G., Baba M., Takao S., et al. Tumor angiogenesis related to growth pattern and lymph node metastasis in early gastric cancer. Chin Med J 1998, 111:1090-1093.
10. Zetter B.R. Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424.
11. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
12. Kim S., Yazici Y.D., Calzada G., Wang Z.Y., Younes M.N., Jasser S.A., et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007, 6:1785-1792.
13. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
14. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
15. van Erp N.P., Gelderblom H., Guchelaar H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:692-706.
16. Meza-Junco J., Sawyer M.B. Metastatic gastric cancer - focus on targeted therapies. Biologics 2012, 6:137-146.
17. Martin-Richard M., Gallego R., Pericay C., Garcia Foncillas J., Queralt B., Casado E., et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2013, 31:1573-1579.
18. Zhu Y., Li J., Li W., Zhang Y., Yang X., Chen N., et al. The biocompatibility of nanodiamonds and their application in drug delivery systems. Theranostics 2012, 2:302-312.
19. Mochalin V.N., Shenderova O., Ho D., Gogotsi Y. The properties and applications of nanodiamonds. Nat Nanotechnol 2012, 7:11-23.
20. Zhang Q.W., Mochalin V.N., Neitzel I., Hazeli K., Niu J.J., Kontsos A., et al. Mechanical properties and biomineralization of multifunctional nanodiamond-PLLA composites for bone tissue engineering. Biomaterials 2012, 33:5067-5075.
21. Vaijayanthimala V., Cheng P.Y., Yeh S.H., Liu K.K., Hsiao C.H., Chao J.I., et al. The long-term stability and biocompatibility of fluorescent nanodiamond as an invivo contrast agent. Biomaterials 2012, 33:7794-7802.
22. Kuo Y., Hsu T.Y., Wu Y.C., Chang H.C. Fluorescent nanodiamond as a probe for the intercellular transport of proteins invivo. Biomaterials 2013, 34:8352-8360.
23. Wang F., Liu J. Nanodiamond decorated liposomes as highly biocompatible delivery vehicles and a comparison with carbon nanotubes and graphene oxide. Nanoscale 2013, 5:12375-12382.
24. Li J., Zhu Y., Li W., Zhang X., Peng Y., Huang Q. Nanodiamonds as intracellular transporters of chemotherapeutic drug. Biomaterials 2010, 31:8410-8418.
25. Chow E.K., Zhang X.Q., Chen M., Lam R., Robinson E., Huang H., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Trans Med 2011, 3:73ra21.
26. Zhang X.Q., Lam R., Xu X., Chow E.K., Kim H.J., Ho D. Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv Mater 2011, 23:4770-4775.
27. Moore L., Chow E.K., Osawa E., Bishop J.M., Ho D. Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Adv Mater 2013, 25:3532-3541.
28. Shimkunas R.A., Robinson E., Lam R., Lu S., Xu X.Y., Zhang X.Q., et al. Nanodiamond-insulin complexes as pH-dependent protein delivery vehicles. Biomaterials 2009, 30:5720-5728.
29. Xiao J., Duan X., Yin Q., Zhang Z., Yu H., Li Y. Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer. Biomaterials 2013, 34:9648-9656.
30. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007, 6:231-248.
31. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012, 64:557-570.
32. Choi H.S., Liu W., Liu F., Nasr K., Misra P., Bawendi M.G., et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol 2010, 5:42-47.
33. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 2008, 26:799-807.
34. Liu K.K., Wang C.C., Cheng C.L., Chao J.I. Endocytic carboxylated nanodiamond for the labeling and tracking of cell division and differentiation in cancer and stem cells. Biomaterials 2009, 30:4249-4259.
35. Rojas S., Gispert J.D., Martin R., Abad S., Menchon C., Pareto D., et al. Biodistribution of amino-functionalized diamond nanoparticles. Invivo studies based on 18F radionuclide emission. ACS Nano 2011, 5:5552-5559.
36. Zhang Z., Ma L., Jiang S., Liu Z., Huang J., Chen L., et al. Aself-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. JControl Release 2013, 166:30-37.
37. Gao F., Zhang Z., Bu H., Huang Y., Gao Z., Shen J., et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. JControl Release 2011, 149:168-174.
38. Zhang Z., Gao F., Bu H., Xiao J., Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: invitro characteristics and absorption mechanism in rats. Nanomedicine NBM 2012, 8:740-747.
39. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Makila E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
40. Yang K., Gong H., Shi X., Wan J., Zhang Y., Liu Z. Invivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. Biomaterials 2013, 34:2787-2795.
41. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
42. Romano F., Garancini M., Uggeri F., Degrate L., Nespoli L., Gianotti L., et al. Surgical treatment of liver metastases of gastric cancer: state of the art. World J Surg Oncol 2012, 10:157.